Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.01
+0.06 (1.32%)
At close: Sep 2, 2025, 4:00 PM
5.00
0.00 (-0.10%)
After-hours: Sep 2, 2025, 4:00 PM EDT
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $1.21M in the quarter ending June 30, 2025, a decrease of -60.52%. This brings the company's revenue in the last twelve months to $19.00M, down -75.91% year-over-year. In the year 2024, Vir Biotechnology had annual revenue of $74.21M, down -13.90%.
Revenue (ttm)
$19.00M
Revenue Growth
-75.91%
P/S Ratio
35.71
Revenue / Employee
$46,569
Employees
408
Market Cap
695.28M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VIR News
- 8 days ago - Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 26 days ago - Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Business Wire
- 27 days ago - Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
- 4 weeks ago - Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
- 5 weeks ago - Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Business Wire
- 5 weeks ago - Vir Biotechnology: Hep B And Cancer Projects March On - Seeking Alpha
- 6 weeks ago - Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire